1887

Abstract

Hepatitis B virus (HBV) infections represent a global health problem, since these account for 350 million chronic infections worldwide that result in 500 000–700 000 deaths each year. Control of viral replication and HBV-related disease and mortality are of utmost importance. Because the currently available antiviral therapies all have major limitations, new strategies to treat chronic HBV infection are eagerly awaited. Six single-domain antibodies (VHHs) targeting the core antigen of HBV (HBcAg) have been generated and three of these bound strongly to HBcAg of both subtype and . These three VHHs were studied as intrabodies directed towards the nucleus or the cytoplasm of a hepatoma cell line that was co-transfected with HBV. A speckled staining of HBcAg was observed in the cytoplasm of cells transfected with nucleotropic VHH intrabodies. Moreover, an increased intracellular accumulation of hepatitis B e antigen (HBeAg) and a complete disappearance of intracellular HBcAg signal were observed with nuclear targeted HBcAg-specific VHHs. These results suggest that HBcAg-specific VHHs targeted to the nucleus affect HBcAg and HBeAg expression and trafficking in HBV-transfected hepatocytes.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.016063-0
2010-03-01
2024-04-19
Loading full text...

Full text loading...

/deliver/fulltext/jgv/91/3/643.html?itemId=/content/journal/jgv/10.1099/vir.0.016063-0&mimeType=html&fmt=ahah

References

  1. Bruss V. 2004; Envelopment of the hepatitis B virus nucleocapsid. Virus Res 106:199–209 [CrossRef]
    [Google Scholar]
  2. Bruss V. 2007; Hepatitis B virus morphogenesis. World J Gastroenterol 13:65–73 [CrossRef]
    [Google Scholar]
  3. Butz K., Denk C., Fitscher B., Crnkovic-Mertens I., Ullmann A., Schröder C. H., Hoppe-Seyler F. 2001; Peptide aptamers targeting the hepatitis B virus core protein: a new class of molecules with antiviral activity. Oncogene 20:6579–6586 [CrossRef]
    [Google Scholar]
  4. Deres K., Schröder C. H., Paessens A., Goldmann S., Hacker H. J., Weber O., Krämer T., Niewöhner U., Pleiss U. et al. 2003; Inhibition of hepatitis B virus replication by drug-induced depletion of nucleocapsids. Science 299:893–896 [CrossRef]
    [Google Scholar]
  5. Feld J., Lee J. Y., Locarnini S. 2003; New targets and possible new therapeutic approaches in the chemotherapy of chronic hepatitis B. Hepatology 38:545–553
    [Google Scholar]
  6. Feng Y., Kong Y. Y., Wang Y., Qi G. R. 2001; Intracellular inhibition of the replication of hepatitis B virus by hammerhead ribozymes. J Gastroenterol Hepatol 16:1125–1130 [CrossRef]
    [Google Scholar]
  7. Gordien E., Rosmorduc O., Peltekian C., Garreau F., Brechot C., Kremsdorf D. 2001; Inhibition of hepatitis B virus replication by the interferon-inducible MxA protein. J Virol 75:2684–2691 [CrossRef]
    [Google Scholar]
  8. Hilleman M. R. 2003; Critical overview and outlook: pathogenesis, prevention, and treatment of hepatitis and hepatocarcinoma caused by hepatitis B virus. Vaccine 21:4626–4649 [CrossRef]
    [Google Scholar]
  9. Ji W., Si C. W. 1997; Inhibition of hepatitis B virus by retroviral vectors expressing antisense RNA. J Viral Hepat 4:167–173 [CrossRef]
    [Google Scholar]
  10. Kann M., Schmitz A., Rabe B. 2007; Intracellular transport of hepatitis B virus. World J Gastroenterol 13:39–47 [CrossRef]
    [Google Scholar]
  11. Kim T. H., Cho E. Y., Oh H. J., Choi C. S., Kim J. W., Moon H. B., Kim H. C. 2006; The degrees of hepatocyte cytoplasmic expression of hepatitis B core antigen correlate with histologic activity of liver disease in the young patients with chronic hepatitis B infection. J Korean Med Sci 21:279–283
    [Google Scholar]
  12. Lavanchy D. 2004; Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 11:97–107 [CrossRef]
    [Google Scholar]
  13. Rabe B., Vlachou A., Pante N., Helenius A., Kann M. 2003; Nuclear import of hepatitis B virus capsids and release of the viral genome. Proc Natl Acad Sci U S A 100:9849–9854 [CrossRef]
    [Google Scholar]
  14. Rosmorduc O., Sirma H., Soussan P., Gordien E., Lebon P., Horisberger M., Brechot C., Kremsdorf D. 1999; Inhibition of interferon-inducible MxA protein expression by hepatitis B virus capsid protein. J Gen Virol 80:1253–1262
    [Google Scholar]
  15. Seeger C., Zoulim F., Mason W. S. 2007; Hepadnaviruses. In Fields Virology , 5th edn. pp 2977–3029 Edited by Knipe D. M., Howley P. M. Philadelphia, PA: Lippincott Williams and Wilkins;
    [Google Scholar]
  16. Serinoz E., Varli M., Erden E., Cinar K., Kansu A., Uzunalimoglu O., Yurdaydin C., Bozkaya H. 2003; Nuclear localization of hepatitis B core antigen and its relations to liver injury, hepatocyte proliferation, and viral load. J Clin Gastroenterol 36:269–272 [CrossRef]
    [Google Scholar]
  17. Serruys B., Van Houtte F., Verbrugghe P., Leroux-Roels G., Vanlandschoot P. 2009; Llama-derived single-domain intrabodies inhibit secretion of hepatitis B virions in mice. Hepatology 49:39–49 [CrossRef]
    [Google Scholar]
  18. Tuttleman J. S., Pourcel C., Summers J. 1986; Formation of the pool of covalently closed circular viral DNA in hepadnavirus-infected cells. Cell 47:451–460 [CrossRef]
    [Google Scholar]
  19. Xu R., Cai K., Zheng D., Ma H., Xu S., Fan S. T. 2003; Molecular therapeutics of HBV. Curr Gene Ther 3:341–355 [CrossRef]
    [Google Scholar]
  20. Yamamoto M., Hayashi N., Takehara T., Ueda K., Mita E., Tatsumi T., Sasaki Y., Kasahara A., Hori M. 1999; Intracellular single-chain antibody against hepatitis B virus core protein inhibits the replication of hepatitis B virus in cultured cells. Hepatology 30:300–307 [CrossRef]
    [Google Scholar]
  21. Ying C., De Clercq E., Neyts J. 2003; Selective inhibition of hepatitis B virus replication by RNA interference. Biochem Biophys Res Commun 309:482–484 [CrossRef]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/vir.0.016063-0
Loading
/content/journal/jgv/10.1099/vir.0.016063-0
Loading

Data & Media loading...

Supplements

Supplementary material 1

PDF
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error